|
|
Vaccine Detail
|
PSA-PAP/KLH-pulsed Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: PSA-PAP/KLH-pulsed Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007152
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- ACPP
gene engineering:
- Preparation: The vaccine consists of dendritic cells pulsed with the prostate-specific tumor associated antigens prostate specific antigen and prostate acid phosphatase, and conjugated to the immunostimulant Keyhole limpet hemocyanin (Onaitis et al., 2002).
- Description: This is for Prostate Cancer (NCT01171729).A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the prostate-specific tumor associated antigens (TAAs) prostate specific antigen (PSA) and prostate acid phosphatase (PAP), and conjugated to the immunostimulant Keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, prostate cancer antigen/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against prostate cancer cells expressing PSA and PAP, which may result in prostate cancer cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy (Onaitis et al., 2002; NCIT_C92573).
|
| Host Response |
|
|
| References |
NCIT_C92573: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C92573]
NCT01171729: [https://clinicaltrials.gov/ct2/show/NCT01171729]
Onaitis et al., 2002: Onaitis M, Kalady MF, Pruitt S, Tyler DS. Dendritic cell gene therapy. Surgical oncology clinics of North America. 2002; 11(3); 645-660. [PubMed: 12487060].
|
|
